The European Medicines Agency (EMA) has been responsible for the authorisation of innovative and biotechnologically manufactured medicinal products in a centralised procedure since 1995. Before finalising the assessment process, the responsible committee can have a GMP inspection carried out. In the mutual recognition authorisation procedure, the EMA has a mediating function in the event of differences of opinion between the Member States concerned.
[GMP Compliance Adviser, Chapter B.2]
You can find out more about this topic:
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business!